Cynvenio Biosystems said this week that it expects to gain CLIA certification in the next few weeks for its circulating tumor cell technology. The company then plans to clinically validate its CTC sequencing service and a number of targeted PCR assays for isolated CTCs, which the company already offers in the research setting.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.